Tracleer approvable letter
Executive Summary
Actelion expects to launch endothelin receptor agonist Tracleer (bosentan) by the end of 2001 pending discussions with FDA on liver toxicity risk management programs and labeling. FDA deemed the pulmonary hypertension drug "approvable" Sept. 17